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Summary: A gonorrhea vaccine offering partial protection for several years, pragmatically 
targeted to people testing for gonorrhea due to symptoms or screening due to sexual risk behavior, 
could substantially reduce gonorrhea incidence, combating increases in antibiotic resistance. 
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ABSTRACT 
Background. Gonorrhea incidence is increasing rapidly in many countries, whilst antibiotic 
resistance is making treatment more difficult. Combined with evidence that MeNZB and Bexsero 
meningococcal vaccines are likely partially-protective against gonorrhea, this has renewed interest 
in a gonococcal vaccine, and several candidates are in development. Key questions are how 
protective a vaccine needs to be, how long protection needs to last, and how should it be targeted. 
We assessed vaccination’s potential impact, and the feasibility of achieving WHO’s target 90% 
reduction in gonorrhea incidence 2016-2030, by comparing realistic vaccination strategies under a 
range of scenarios of vaccine efficacy and duration of protection, and emergence of 
extensively-resistant gonorrhea. 
Methods. We developed a stochastic transmission-dynamic model, incorporating asymptomatic 
and symptomatic infection and heterogeneous sexual behavior in men-who-have-sex-with-men 
(MSM). We used data from England, which has a comprehensive, consistent nationwide 
surveillance system. Using particle Markov Chain Monte Carlo methods we fitted the model to 
gonorrhea incidence in 2008-17, and then used Bayesian forecasting to examine an extensive range 
of scenarios. 
Results. Even in the worst-case scenario of untreatable infection emerging, the WHO target is 
achievable if all MSM attending sexual health clinics receive a vaccine offering ≥52% protection 
for ≥6 years. A vaccine conferring 31% protection (as estimated for MeNZB) for 2-4 years, could 
reduce incidence in 2030 by 45% in the worst-case scenario, and by 75% if >70% of resistant 
gonorrhea remains treatable. 
Conclusions. Even a partially-protective vaccine, delivered through a realistic targeting strategy, 
could substantially reduce gonorrhea incidence, despite antibiotic resistance. 
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INTRODUCTION 
The World Health Organization (WHO) classifies Neisseria gonorrhoeae as a priority bacterial 
pathogen, due to the high global burden of infection combined with evolution and global spread of 
resistance to every antibiotic historically used against it[1,2]. Countries such as the USA[3], 
Australia[4], UK[5] and other European countries[6] have reported rapidly growing epidemics, 
particularly among men-who-have-sex-with-men (MSM).  
 
Due to the threat of antibiotic resistant gonorrhea it has been suggested that that vaccination may be 
the only sustainable solution to gonorrhea control[7]. Vaccine development has been hampered by 
genetic variability in the gonococcus, and the lack of a measurable correlate of protection and a 
suitable animal model[8]. None of four vaccine candidates that progressed to clinical trials was 
effective[9]. However, indication that vaccination against gonorrhea might be feasible came from 
surveillance reports from Cuba and New Zealand showing a decline in gonorrhea incidence 
following vaccination initiatives against the closely-related Neisseria meningitidis[10–12]. A 
retrospective case-control study of 15,000 young adults in New Zealand who had received an 
outer-membrane vesicle meningococcal B vaccine (MeNZB) estimated 31%(95%CI:21%-39%) 
protection against N. gonorrhoeae[13], and a recent study reported that the Bexsero 
meningococcal B vaccine may be more protective than this[14]. There are now multiple vaccine 
candidates in preclinical development[11,15]. 
 
Key questions to inform development and use of vaccines to control gonorrhea are the preferred 
product characteristics of a gonorrhea vaccine (i.e. what efficacy and duration of protection are 
required)[16], and how best to deploy vaccines to decrease the overall burden of disease[17–19]. In 
2016, the WHO announced a global health sector strategy on sexually transmitted infections, with 
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a target of 90% reduction in gonorrhea incidence by 2030[2]. We investigated how protective and 
long-lasting a vaccine would need to be to reduce total incidence below the WHO target using a 
stochastic model (accounting for variability due to random chance) of gonorrhea epidemiology in 
MSM in England calibrated to recent incidence data[20,21], with varying future levels of antibiotic 
resistance. We compared the impact and efficiency of three realistic vaccination strategies, studied 
the interplay between vaccination and antibiotic resistance levels, and quantified the effect of 
differing levels of vaccine uptake. Finally, we assessed the potential impact of vaccines with a 
partially protective profile similar to MeNZB. 
 
METHODS 
Model structure 
We developed a stochastic compartmental transmission-dynamic model to project the future 
course of a gonorrhea epidemic under different vaccination scenarios, considering 
antibiotic-sensitive and antibiotic-resistant (ABR) strains. We used data from England, which has 
comprehensive, consistent, nationwide surveillance system[20,21]. We considered transmission 
within men-who-have-sex-with-men (MSM) as they have the highest per-capita rate of infection. 
We simulated gonorrhea transmission from 2008 to 2030, using surveillance data 2008-2017 for 
calibration and then projecting scenarios to 2030. We extended a previous model[22] to 
incorporate heterogeneity in sexual risk behavior by dividing the population into low- and 
high-risk groups with characteristic rates of sexual partner change, based on the Natsal-3 
survey[23]. 
 
Following acquisition of gonorrhea, individuals initially pass through a short incubation period, 
after which they either develop symptoms or remain asymptomatically infected (Figure 1). 
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Surveillance data are not stratified by infection site (rectum, pharynx, urethra), hence estimated 
parameters can be interpreted as an average across infection sites. Infected individuals are treated 
after seeking care due to symptoms or after testing positive in sexual health screening. Treated 
individuals become uninfected, except for a proportion of those infected with the ABR strain for 
whom treatment fails, leading to persistent infection for which the same dynamics are assumed as 
for asymptomatic cases[22]. Recovery from untreated infection also occurs naturally over time. 
Infection does not confer natural immunity[24,25]. We consider a situation in which the ABR 
strain emerges globally in 2020 and is imported into the highly-sexually-active group. 
 
Model calibration and accounting for uncertainty 
We calibrated the model, in a Bayesian framework, to the annual number of gonorrhea cases in 
MSM in England between 2008-2017[20]. These data were considered as the observed realizations 
of a complex underlying unobserved Markov process (Figure 1). Prior parameter distributions 
were based on published evidence where available, and uninformative priors used otherwise. All 
unknown parameters were calibrated, with a particle filter[26] used to produce an unbiased 
estimate of the likelihood of the observed data given the model, in a particle Markov Chain Monte 
Carlo (pMCMC) process which produced a posterior sample of the model parameters given the 
observed data[27,28]. We accounted for uncertainty in estimated parameters by using 1,000 
samples from the joint posterior distribution. Full details of the model, the parameter values, and 
prior distributions are in Supplementary Material. We varied the frequency of treatment failure for 
the ABR strain (0%-100%). 
 
Vaccination scenarios 
We considered 500 hypothetical vaccine profiles of varying protection (1%-100%) and duration 
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(1-20 years). Partial protection was assumed to be “leaky” (i.e. degree-type)[29], with all vaccinees 
being less likely, but still able, to acquire infection. Vaccine protection only affects the probability 
of acquisition and does not affect progression through stages of infection after acquisition. 
 
We considered three realistic strategies for the vaccine deployment: “vaccination-before-entry” 
into the sexually-active population (where adolescents are vaccinated before they become 
sexually-active); “vaccination-on-diagnosis” with gonorrhea (a practical strategy designed to 
target those most at risk, as gonorrhea diagnosis is used as a proxy measure for risk of future 
exposure); and “vaccination-on-attendance” at a sexual health clinic for any reason, including 
seeking testing and treatment for symptoms or asymptomatic screening (which broadens the 
eligibility criteria of the “vaccination-on-diagnosis” strategy to include all clinic attendees). 
Vaccine uptake among eligible individuals was varied (50%-100%) for each strategy. Scenarios 
were compared to baseline projections without vaccination. 
 
RESULTS 
The model was successfully calibrated, with simulated epidemic curves being in close agreement 
with the observed data for all years (Figure 2A). For example, the model estimated 
21,900(95%CI:18,900-25,200) cases in 2017, in good agreement with the data (21,300 cases)[20]. 
In the best-case scenario, with no worsening of resistance, the model predicted 
23,500(20,000-27,600) cases in 2030. However, emergence of an antibiotic-resistant (ABR) strain 
causing treatment failures would increase the projected number of cases (Figure 2B): the higher the 
frequency of treatment failure, the greater the onward transmission of drug-resistant infections and 
the greater the predicted number of cases. In the worst-case scenario of 100% treatment failure for 
the ABR strain, the model predicted 48,500(23,600-80,100) gonorrhea cases in 2030. 
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Focusing on the worst-case scenario where treatment of ABR gonorrhea always failed, we assessed 
the impact of each hypothetical vaccine profile (i.e. combination of level and duration of 
protection) under the three deployment strategies by calculating the expected reduction in 
gonorrhea cases in 2030 (Figure 3) compared with no vaccination. Achieving the WHO target 
corresponds to <1,800 cases in MSM in England in 2030[2]. In the vaccination-before-entry 
strategy, even a fully-protective vaccine lasting 20 years achieved only a 34%(17%-52%) 
reduction in expected cases in 2030 (Figure 3A), well below the WHO target. Under this strategy 
only adolescents entering the sexually-active population are vaccinated, so vaccine coverage 
across the entire MSM population is slow to accumulate, reducing the impact of the intervention. 
Vaccination-on-diagnosis with this idealized vaccine also fell short of the WHO target but 
achieved a much higher reduction of 92%(82%-98%) (Figure 3B). By extending vaccination to all 
MSM tested for gonorrhea (i.e. vaccination-on-attendance, both those seeking care for symptoms 
and those screened in the absence of symptoms), the WHO target could be achieved using a ≥52% 
effective vaccine protecting for ≥6 years, or equivalently a ≥70% effective vaccine lasting ≥3 years 
(Figure 3C). Under the vaccination-on-diagnosis and vaccination-on-attendance strategies, a 
vaccine lasting eight years had similar benefits to one offering the same protection for a longer 
period (Figure 3B,C). 
 
Under the vaccination-before-entry strategy, the proportion of MSM protected in 2030 was <20% 
irrespective of the duration of vaccine protection (Figure 3D), because most individuals were 
already sexually-active, and therefore ineligible for vaccination. Under the 
vaccination-on-diagnosis strategy the protected proportion was generally higher (Figure 3E) 
because more individuals were eligible for vaccination. Interestingly, the proportion protected 
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decreased as vaccine efficacy increased, because a highly-protective vaccine reduced transmission, 
which in turn reduced the number of cases treated and hence individuals vaccinated alongside 
treatment. This effect also occurred under the vaccination-on-attendance strategy, but it was much 
less pronounced as patients attending for screening were also vaccinated. The maximum 
proportion protected under vaccination-on-attendance was 86%(85.8%-86.4%), if the duration of 
protection were 20 years (Figure 3F). 
 
We assessed how the impact of vaccination would differ depending on the treatability of the 
emergent gonorrhea ABR strain and the uptake of vaccination by eligible MSM (Figure 4). The 
less treatable the ABR strain the more protective a vaccine would need to be to meet the WHO 
target. The vaccination-before-entry strategy was unable to achieve the WHO target, no matter 
how protective and long-lasting the vaccine, even in the best-case scenario of no treatment failure. 
The vaccination-on-diagnosis strategy met the WHO target for a range of vaccine profiles, in 
scenarios where at least 30% of ABR cases were treatable, provided almost all eligible MSM 
accepted the vaccine when offered and protection lasted almost 20 years (Figure 4A). With 75% 
vaccine uptake vaccination-on-diagnosis could not meet the target if ABR treatment failure 
exceeded 60% (Figure 4B). With an uptake of only 50%, the target was not met even in the 
best-case scenario of no treatment failure. The lower the uptake, the greater the vaccine protection 
level and/or duration required to achieve a given impact (Figure 4A-B). The 
vaccination-on-attendance strategy resulted in much higher coverage, meaning that less-protective 
vaccines were able to achieve the WHO target (Figure 4C). For example, in the absence of 
treatment failure, a 35%-protective vaccine lasting ten years could meet the WHO target, whereas, 
under the vaccination-on-diagnosis strategy, the vaccine would need to be 80%-protective. At the 
other extreme, if treatment of ABR cases always failed then the WHO target could be achieved 
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with the vaccination-on-attendance strategy but would require for example a protection duration of 
six years and efficacy of 50%-75% depending on uptake (Figure 4C-E). 
 
Currently the only vaccine with estimated effectiveness of protection against gonorrhea is MeNZB, 
which offers 21%-39% protection[13]. While there are no robust estimates of the duration of 
protection of MeNZB, we modeled a conservative 2-4 year duration in line with initial indications 
[13]. We considered deployment of a similar vaccine using the three strategies, and compared the 
expected number of cases in 2030, the proportion of ABR, the proportion of protected MSM and 
the number of cases averted over ten years per person vaccinated (Figure 5). If there were no 
emergence of ABR gonorrhea, then a vaccine with properties like MeNZB could have a substantial 
impact on the projected epidemic. With uptake of 100%, vaccination-on-diagnosis would reduce 
the expected incidence in 2030 by 41%(18%-65%), from 23,500(20,000-27,600) to 
13,900(8,200-18,700), and vaccination-on-attendance would reduce incidence by 75%(40%-98%) 
to 5,900(450-13,600) cases. The greater impact of vaccination-on-attendance was due to much 
greater coverage, with much lower efficiency: the mean cases averted per vaccination was 
0.10(0.07-0.13) compared with 0.51(0.32-0.75) for vaccination-on-diagnosis. It should be noted 
that even vaccination-on-attendance was insufficient to meet the WHO in 85% of the simulations. 
The vaccination-before-entry strategy was in effective with a MeNZB-like vaccine, achieving only 
a 7%(0%-23%) reduction in 2030 incidence, even without emergence of ABR. 
 
The greater the frequency of treatment failure for ABR infections, the greater the predicted 
incidence in 2030 and the less likely the epidemic could be controlled by a MeNZB-like vaccine 
(Figure 5A). Vaccination-on-attendance was always the most effective strategy, regardless of the 
treatability of the resistant strain. In the extreme case where ABR treatment always failed, 
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vaccination-on-attendance with a MeNZB-like vaccine with 100% uptake reduced the expected 
number of cases by 45%(18%-77%). This equated to the prevention of around 20,900 cases in 
2030, reducing the expected diagnoses from 48,500(23,600-80,100) to 27,600(8,000-55,800). The 
proportion of cases expected to be ABR in 2030 was unaffected by vaccination, regardless of the 
vaccination strategy: vaccination reduced the expected diagnoses of both the resistant and 
susceptible strains proportionately (Figure 5B). The proportion of individuals protected by the 
vaccine, and the corresponding number of vaccine doses dispensed, depended more on the 
vaccination strategy than on the treatability of the ABR strain (Figure 5C), with 
vaccination-on-attendance resulting in a much higher proportion of protected individuals. 
Vaccination-on-diagnosis proved to be the most efficient strategy overall, with on average about 
one averted case for every two vaccine doses administered, which remained constant for almost all 
resistant strains (Figure 5D). 
 
DISCUSSION 
We developed a stochastic transmission-dynamic model of gonorrhea that incorporates 
heterogeneity in sexual behavior and considers use of health services for care-seeking and 
screening. The model was calibrated using 10 years’ data using Bayesian inference methods to 
estimate model parameters, and then used to examine the population-level impact of potential 
vaccines, administered via three realistic strategies. Our results show that even a 
partially-protective vaccine could be valuable in controlling the gonorrhea epidemic and 
combating the spread of antibiotic resistance. Provided infections remain ultimately treatable, 
vaccinating all MSM attending sexual health clinics from 2020 onwards with a 45%-protective 
vaccine lasting at least four years, or a 60%-protective vaccine lasting at least two years, would be 
sufficient to meet the WHO target of a 90% reduction in annual incidence between 2016 and 
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2030[2]. Whilst this requires greater protection than the 31%(95%CI:21%-39%) that MeNZB 
appears to offer[13], Bexsero is expected to be more protective due to its Neisserial heparin 
binding antigen component[14]. In addition to protecting against infection with gonorrhea, 
vaccination with MeNZB might also be protective against severe disease if infection is 
nevertheless acquired[30]. 
 
We investigated the interplay between antibiotic resistance and vaccination, making the 
conservative (and likely pessimistic) assumption that antibiotic resistance did not incur a fitness 
cost. In the extreme case where treatment for the ABR strain always fails, a 52%-protective vaccine 
lasting six years, administered to all MSM attending sexual health clinics would be necessary to 
achieve the WHO target. 
 
Imperfect vaccines are usually modeled as providing either take-type protection (where a 
proportion of vaccinees are fully protected and the remainder not at all), or degree-type protection 
(where all vaccinees have a partial reduction in the probability of infection upon exposure)[29]. 
Here we used the latter, even though it is unknown what type of protection a future gonorrhea 
vaccine might provide, or indeed if it would conform to one type or another or a mixture of both. 
For vaccines with degree-type protection, greater coverage is necessary to reduce the prevalence of 
infection than with take-type protection[31], so that our choice is conservative. Furthermore, a 
take-type protection vaccine is similar in result to the effect of partial uptake for a highly protective 
degree-type vaccine, which we considered separately (Figure 4). Degree-type protection could 
conceivably manifest as a reduction in infectiousness[32], rather than the reduction in 
susceptibility we model here; previous modeling has found the impact to be similar[17]. 
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Uptake of vaccination is clearly a critical determinant for the success of any vaccination program, 
and societal concerns about vaccines are a potential barrier to achieving high coverage[12]. 
However, a recent pilot program for human papillomavirus (HPV) vaccine in UK MSM recorded 
uptake of 45%, which is likely to be an underestimate due to incomplete recording[33]. Therefore, 
the 50% uptake scenario we modeled could be considered a realistic lower bound, especially for 
the vaccination-on-diagnosis and vaccination-on-attendance strategies, in which the vaccine would 
be offered to individuals likely to be concerned about gonorrhea infection. 
 
Our study is the first to consider vaccination against gonorrhea in the context of antibiotic 
resistance, and to assess the potential real-world impact that could be achieved using a vaccine with 
protection profile similar to MeNZB as well as potentially superior gonorrhea vaccines, which is 
expected to include Bexsero[14]. Previous modeling studies have focused on assessing the 
potential impact of hypothetical vaccines in small populations of either heterosexual 
individuals[17] or MSM[34]. In accordance with our findings, they concluded that a vaccine of 
moderate level and duration of protection (60% for 10 years) could substantially reduce prevalence 
of infection by >30%[17]. Our analysis is novel in considering the effect of vaccination on the 
scale of all MSM within a country, by comparing alternative realistic deployment strategies, and by 
incorporating the possible global emergence of a new extensively resistant strain, as well as 
incorporating a statistically rigorous fit to incidence data. 
 
We considered scenarios in which sexual health services are able to meet the additional demand 
caused by increasing levels of gonorrhea incidence and antibiotic resistance. However, in recent 
years, access to UK sexual health services has worsened for individuals with symptoms of an acute 
sexually transmitted infection[35]. This insufficient capacity in sexual health clinics could create a 
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vicious circle, where treatment delays cause onward transmission, increased incidence, and further 
unmet treatment need, a situation that would be exacerbated by antibiotic resistance[36,37]. A 
gonococcal vaccine would offer important benefits of easing this pressure by averting infections, 
thereby reducing demand on clinics and avoiding the vicious circle. 
 
There are two important areas for attention by public health researchers and policy-makers: firstly, 
the criteria on which treatment guidelines are formulated, and secondly, the need for well-designed 
vaccine trials which incorporate the aim of improving our understanding of the natural history of N. 
gonorrhoeae. Treatment guidelines are currently based on the proportion of diagnosed cases that 
are drug-resistant, with exceedance of a 5% threshold prompting changes to recommendations. 
However, it is important for policymakers also to consider the total number of resistant cases - 
especially in scenarios where resistant gonorrhea becomes more difficult and costlier to treat, as 
exemplified by a recent case of multi-drug resistant gonorrhea that required three days of inpatient 
treatment with intravenous ertapenem[38]. 
 
Trials of vaccine candidates need to be designed to address important gaps in knowledge, including 
the possibility of perverse outcomes. For example, if vaccination reduces the bacterial load then 
this might reduce transmission by reducing infectivity. Alternatively, it might promote 
transmission if it reduces the probability or severity of symptoms and thereby increases the 
proportion of infections that are left untreated and hence persistent[32]. Not only could persistent 
infections lead to increased transmission, but they may increase the probability of drug resistance 
evolving within asymptomatic hosts[39]. Conversely, the resistance selection pressures could be 
reduced if fewer infections are being treated with antibiotics[18]. The relationship between 
determinants of drug-resistance and antigenicity is not known and trials should monitor the 
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diversity of lineages of N. gonorrhoeae. If a determinant of drug resistance is immunogenic and 
included in the vaccine, then this would enhance the beneficial impact of vaccination, whilst a 
vaccine that is more effective against drug-sensitive strains could increase the relative prevalence 
of resistance. Notwithstanding these interrogations and need for further research, a gonococcal 
vaccine could offer the hope of bringing the current epidemic of gonorrhea under control. 
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FIGURE LEGENDS 
Figure 1. Model structure flow diagram. The population is divided into compartments 
representing different states, with changes of state occurring due to various processes. Individuals 
enter the sexually-active population (arrow 1) at age 15 years. They are initially uninfected (U), 
and belong to a sexual activity group g (low or high). Individuals become infected with either the 
antibiotic-sensitive (ABS) strain (2) or antibiotic-resistant (ABR) strain (3). Infected individuals 
pass through an incubating state (I), before either developing symptoms (4) and entering the 
symptomatic infection state (S), or remaining asymptomatic (5) and entering the asymptomatic 
infection state (A). Symptomatic individuals seek treatment (6) and enter the treatment state (T). 
Asymptomatic infections can be identified through screening and treatment (7), with individuals 
entering the treatment state (T), or there can be natural recovery (8), returning individuals to the 
uninfected state (U). All treated infections are cured (9), with the exception of a proportion of ABR 
infections for which treatment fails, resulting in persistent infection (10). Depending on the 
vaccination strategy, individuals are vaccinated before entry into the sexually-active population 
(VbE, in which case all vaccinees are uninfected), on gonorrhea diagnosis (VoD, with vaccination 
given to those who are treated), or on clinic attendance for gonorrhea screening (VoA, with 
individuals in all states being eligible). Upon vaccination individuals enter corresponding 
compartments indicated with a circumflex (^). Vaccine protection eventually wanes (11), with 
individuals moving into the corresponding compartments without circumflex. Individuals leave the 
sexually-active population at age 65 years, regardless of infection or vaccination status (12). 
 
Figure 2. Simulated annual gonorrhea cases between 2008 and 2030 in the absence of 
vaccination. The model is fitted to data in the period 2008-2017 and then projected beyond that 
period. (A) Number of cases if a novel resistant strain does not emerge. The red line depicts 
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surveillance data; the horizontal line shows WHO target of 90% reduction in incidence relative to 
2016. Shaded areas show 99% posterior predictive intervals, based on 1,000 simulations. (B) 
Expected number of cases in 2030 depending on the frequency of treatment failure for a novel 
antibiotic-resistant strain emerging in 2020. 
 
Figure 3. Impact of different vaccination strategies against gonorrhea, given the emergence 
of a resistant strain in 2020 for which antibiotic treatment always fails. Vaccination was 
implemented from 2020 and administered to individuals entering the sexually-active population 
(A,D), or to patients diagnosed with gonorrhea (B,E), or to patients on clinic attendance (C,F). 
Level (horizontal axes) and duration of protection (vertical axes) were varied. (A,B,C) show the 
mean reduction in the expected number of cases in 2030, whereas (D,E,F) show the proportion of 
MSM protected by the vaccine in 2030. Vaccine profiles (i.e. combinations of level and duration of 
protection) for which the WHO incidence target was achieved by 2030 are highlighted with a 
dotted line (this is only achieved in part of C). 
 
Figure 4. Protection level and duration of vaccine needed to reduce incidence below the 
WHO target by 2030 for gonorrhea strains with varying degrees of resistance. Results are 
shown for vaccination on diagnosis (A,B) or on clinic attendance (C,D,E), under varying levels of 
vaccine uptake: 100% (A,C), 75% (B,D) and 50% (E). The vaccination-before-entry strategy is not 
shown as it did not achieve the WHO target for any scenario considered, and likewise for the 
vaccination-on-diagnosis strategy with an uptake of 50%. 
 
Figure 5. Potential impact and efficiency of a MeNZB-like vaccine. Vaccination was 
implemented before entry into the sexually-active population, on diagnosis, or on clinic 
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attendance. Shaded bars depict 95% predictive interval; diamonds indicate the mean. (A) Expected 
gonorrhea cases in 2030, with the dashed line depicting the WHO target. (B) Proportion of 
gonorrhea cases expected to be resistant in 2030. (C) Proportion of MSM protected by the vaccine 
in 2030. (D) Mean cases averted per course of vaccination. 
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Figure 1 
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Figure 2 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1241/5697289 by U
niversity of W
arw
ick user on 27 January 2020
 27 
Figure 3 
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Figure 4 
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Figure 5 
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